Article Versions Notes

Sridhar A, Gunning TS, Della Pia A, Zhang X, Ahn J, Sinclaire B, Lukasik B, Cho C, Donato ML, Kaur S, et al. Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study. Hemato. 2025; 6(1):3. https://doi.org/10.3390/hemato6010003

Sridhar, Aishwarya, Thomas S. Gunning, Alexandra Della Pia, Xiaopei Zhang, Jaeil Ahn, Brittany Sinclaire, Brittany Lukasik, Christina Cho, Michele L. Donato, Sukhdeep Kaur, and et al. 2025. "Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study" Hemato 6, no. 1: 3. https://doi.org/10.3390/hemato6010003

Sridhar, A., Gunning, T. S., Della Pia, A., Zhang, X., Ahn, J., Sinclaire, B., Lukasik, B., Cho, C., Donato, M. L., Kaur, S., Suh, H. C., Leslie, L. A., Feldman, T. A., Goy, A. H., & Ip, A. (2025). Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study. Hemato, 6(1), 3. https://doi.org/10.3390/hemato6010003